QF0159 Marketing Release Record

Novocastra Villin
Clone CWWB1
1 mL, 0.1 mL lyophilized NCL-VILLIN F P (HIER) W RUO*
1 mL liquid NCL-L-VILLIN ASR
7 mL BOND ready-to-use PA0106 P (HIER) IVD
Analyte Specific Reagent. Analytical and performance characteristics are
not established.
Novocastra Vimentin
Clone SRL33 Reference Range
1 mL, 0.1 mL liquid NCL-L-VIM-572 P (HIER) W
7 mL BOND ready-to-use PA0033 P (HIER) IVD
Clone V9
1 mL, 0.1 mL lyophilized NCL-VIM-V9 F P (HIER) W
1 mL liquid NCL-L-VIM-V9 F P (HIER) W IVD
7 mL ready-to-use RTU-VIM-V9 F P (HIER) IVD
Clone VIM 3B4
1 mL lyophilized NCL-VIM F P (Enzyme) W
Antigen Background
RUO*
Eukaryotic cells contain a number of types of cytoplasmic filamentous
proteins, microtubule, microfilaments and intermediate-sized filaments (IF).
Vimentin, a 57 kD protein that is an intermediate filament is reported to be
expressed in most cells of mesenchymal origin, including fibroblasts,
endothelial cells, smooth muscle, melanocytes as well as T and B
lymphocytes.
Astrocytoma: immunohistochemical staining for vimentin using NCL-L-VIM-572.
Note intense cytoplasmic staining of astrocytes. Paraffin section.
IVD
IVD
Novocastra WAF1 Protein (p21, C1P1)
Clone 4D10
1 mL, 0.1 mL lyophilized NCL-WAF-1 P (HIER)
1 mL liquid NCL-L-WAF-1 P (HIER) RUO*
The gene encoding WAF1, also termed p21, is transcriptionally regulated by
the suppressor protein, p53. Overexpression of WAF1 is growth suppressive,
possibly by inhibiting the activity of cyclin/CDK complexes. One
consequence of WAF1 binding to cyclin/CDK complexes is the inhibition of
Rb protein phosphorylation. Induction of WAF1 expression requires wild
type p53 activity in cells undergoing p53 dependent G1 arrest or apoptosis.
Mutation of the p53 gene is a common event in human cancer and results in
the failure to produce WAF1. The effect of this may lead to uncontrolled cell
proliferation.
Novocastra Wilms' Tumor
Clone WT49 Reference Range
1 mL, 0.1 mL liquid NCL-L-WT1-562 P (HIER)
7 mL BOND ready-to-use PA0562 P (HIER)
Antigen Background
RUO*
Wilms' tumor protein (WT1) has a role in transcriptional regulation and is
expressed in the kidney and a subset of hematopoietic cells. Alteration of
transcription factor function is a common mechanism in oncogenesis. The
WT1 protein contains a DNA binding domain and any deletions or point
mutations of the WT1 gene which destroy this activity result in the
development of the childhood nephroblastoma Wilms' tumor and Denys-
Drash syndrome. The description of WT1 involvement in nephroblastoma is
not clear. Expression of WT1 protein by immunohistochemistry is never
observed (or exceptionally rare) in breast cancer and negativity is considered
a useful marker to distinguish breast carcinoma metastases from serous
ovary primary carcinomas. This is at variance with observations regarding
mRNA in these tumors, but this is a still unresolved and complex issue.
Product Specific Information
Endothelial cells are prevalently negative using clone WT49. These cells are
otherwise immunoreactive with clone 6FH2.
Human Wilms’ tumor: immunohistochemical staining for WT1 using NCL-L-WT1-562.
Note intense nuclear staining of malignant cells. Paraffin section.
F Frozen I Immunofluorescence E Electron microscopy
P Paraffin C Flow cytometry O Other applications
W Western blotting
IVD
IVD
/ 111
Primary Antibodies